Investigating novel treatments for a brighter tomorrow
See Enrolling StudiesClinical trials are carefully designed research studies that explore if a new medication or device is safe and effective for humans. These studies may also show which medical approaches work best for certain illnesses or groups of people.
Uptown Research Institute is currently enrolling patients in clinical trials for the following:
Definium MM120-311 Ascend
This study is designed to evaluate the efficacy of a single dose of 100 µg of MM120 (D-lysergic acid diethylamide D-tartrate), versus placebo, for the treatment of depression symptoms.
This study is sponsored by Definium Therapeutics (formerly Mind Medicine).
MycoMedica 26-MLS101-104
This study is indicated for premenopausal adult females living with Premenstrual Dysphoric Disorder (PMDD).
The goal of this study is to assess the safety and tolerability of intermittent low doses of MLS101 (psilocybin) compared with placebo, administered approximately every 72 hours in the luteal phase of the menstrual cycle. This study involves 10 on-site visits, including 6 dosing days, and up to 7 phone call visits. The dosing day appointments are 8 to 9 hours long. Participants are randomized to receive 6 doses of either placebo or MLS101 at 2mg, 4mg, or 6mg.
This study is sponsored by MycoMedica Life Sciences, PBC.
Transcend TSND201-PTSD-301
For adults living with Post Traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the efficacy, safety, and tolerability of TSND-201 for the treatment of PTSD symptoms compared to placebo
This study is sponsored by Transcend Therapeutics, Inc.
Neurocrine-3029
For adults with schizophrenia who warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.
This study is sponsored by Neurocrine Biosciences, Inc.
Amani Therapeutics AM-01-001
The purpose of this study is to assess the safety and tolerability of clozapine plus mitiperstat, at three dose levels of mitiperstat, compared to clozapine alone for adults with treatment-resistant schizophrenia.
Eligible participants will be assigned one of four treatments (A, B, C, or D) to receive clozapine co-administered with one of three different doses of mitiperstat (2.5 mg, 5.0 mg, and 7.5 mg), or clozapine alone (without mitiperstat). The starting dose of clozapine will be 12.5 mg in the morning on Day 1 for all treatment groups and the dose will increase, as tolerated. The starting dose of mitiperstat will be 2.5 mg QD
This study is sponsored by Amani Therapeutics.
Neurocrine-3032
For adults with schizophrenia who do not warrant inpatient hospitalization.
The goal of this study is to assess the efficacy, safety, and tolerability of NBI-1117568 in adults with schizophrenia.
This study is sponsored by Neurocrine Biosciences, Inc.
Johnson & Johnson 67953964SCH1001
This study is for adults with schizophrenia looking for an adjunctive treatment method.
The purpose of this study is to assess the safety, tolerability, and efficacy of Aticaprant as an adjunctive treatment for adults living with schizophrenia. All participants will continue their current treatment with permitted background antipsychotic medications (oral or long-acting injectable) at the same dose, without change, taken approximately around the same time of the day (if oral) as prior to entering the study.
This study is sponsored by Johnson & Johnson.
Maplight ML-007C-MA-212 [De Novo]
This study is indicated for adults with schizophrenia looking for outpatient treatment.
The goal of this study is to assess the long-term efficacy, safety, and tolerability of ML-007C-MA in adult participants living with symptoms of schizophrenia. For this study, ML-007C-MA is taken orally BID (twice a day), approximately 12 hours apart, within approximately 1 hour of consuming food. ML-007C-MA is provided as a tablet in dose strengths of 105/1.5 mg, 105/3 mg, and 165/3 mg. The dose of 210/3 mg requires the ingestion of two 105/1.5 mg tablets. Study drug will be dispensed to participants to take home.
This study is sponsored by Maplight Therapeutics.
Learn MoreLB Pharmaceuticals LB-102-010
This study is for adults with schizophrenia who are currently stable, but are experiencing either an inadequate response to their current antipsychotic medication and desire to change medications, or experiencing issues with side effects, general tolerability, or overall effectiveness of their current antipsychotic medication and desire to change medications.
The purpose of this study is to evaluate the long-term safety and tolerability of LB-102 with doses from 50mg to 100mg administered once daily in adults with schizophrenia. All qualified participants will receive LB-102 100mg QD. The dose of LB-102 will be evaluated at each following study visit and adjusted if needed, ranging from 50mg to 100mg.
This study is sponsored by LB Pharmaceuticals.
Uptown Research Institute offers an array of clinical trials across a variety of psychiatric and medical conditions.
We follow ethical and legal guidelines to meet FDA requirements, protect patient volunteers, preserve the integrity of the study, and ensure privacy.
In order to participate in a clinical trial, patients must sign an Informed Consent Form. This document describes the rights and responsibilities for participants, including the voluntary nature of participation.
Criteria For Enrollment
Not every person can participate in a clinical trial. All clinical trials have guidelines regarding who can participate, such as:
Inclusion Criteria, or factors that allow someone to participate in a clinical research trial
Exclusion Criteria, or factors that exclude someone from participation in a clinical research trial
Inclusion and exclusion criteria may include factors like:
Age
Type and stage of disease
Previous treatment history
Other medical conditions